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Abstract 
Despite extensive understanding of sleep regulation, the molecular-level cause and function 
of sleep are unknown. I suggest that they originate in individual neurons and stem from increased 
production of protein fragments during wakefulness. These fragments are transient parts of protein 
complexes in which the fragments were generated. Neuronal Ca
2+
 fluxes are higher during 
wakefulness than during sleep. Subunits of transmembrane channels and other proteins are cleaved 
by Ca
2+
-activated calpains and by other nonprocessive proteases, including caspases and secretases. 
In the proposed concept, termed the fragment generation (FG) hypothesis, sleep is a state during 
which the production of fragments is decreased (owing to lower Ca
2+
 transients) while 
fragment-destroying pathways are upregulated. These changes facilitate the elimination of 
fragments and the remodeling of protein complexes in which the fragments resided. The FG 
hypothesis posits that a proteolytic cleavage, which produces two fragments, can have both 
deleterious effects and fitness-increasing functions. This (previously not considered) dichotomy can 
explain both the conservation of cleavage sites in proteins and the evolutionary persistence of sleep, 
because sleep would counteract deleterious aspects of protein fragments. The FG hypothesis leads 
to new explanations of sleep phenomena, including a longer sleep after sleep deprivation. Studies in 
the 1970s showed that ethanol-induced sleep in mice can be strikingly prolonged by 
intracerebroventricular injections of either Ca
2+
 alone or Ca
2+
 and its ionophore
1-3
. These results, 
which were never interpreted in connection to protein fragments or the function of sleep, may be 
accounted for by the FG hypothesis about molecular causation of sleep. 
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Introduction 
The modern era of sleep research began with the 1949 discovery of the reticular activating 
system in the brainstem that controls wakefulness and sleep
4
. Over the last six decades, great strides 
have been made in studies of sleep regulation. However, the molecular-level function of sleep 
remains unknown. This lack of understanding is particularly remarkable vis-à-vis the broad 
knowledge about neuronal circuits that control sleep in animals, including humans. Sleep appears to 
be universal among vertebrates, from fishes to mammals. Sleep-like states are also present in 
invertebrates such as the fly Drosophila melanogaster (~10
5
 neurons) and even the nematode 
Caenorhabditis elegans (~300 neurons). Although it is likely that all vertebrates sleep and that sleep 
in Drosophila and other invertebrates is fundamentally similar to mammalian sleep, these issues 
remain to be settled definitively. Neuronal pathways that regulate sleep are linked to circadian 
circuits that control daily rhythms. However, circadian aspects of sleep do not define it entirely, 
because sleep has, in addition, specific homeostatic properties, described below. The evident 
complexity of sleep, including its distinct stages in mammals, such as rapid eye movement (REM) 
and non-rapid eye movement (NREM) sleep, suggests that sleep may have several causes and 
functions. A new hypothesis described below considers, in the spirit of Occam’s razor, one 
molecular function of sleep. 
In mammals, sleep can be initiated in small networks of neurons in the cortex and other 
regions of the brain
5-9
. Despite profound anatomical differences and size disparities between, for 
example, the human and Drosophila brains, the molecular designs of neurons are highly similar in 
these divergent organisms. Given this experimental background, I suggest that the fundamental 
cause and function of sleep may reside in individual neurons, as distinguished from neuronal 
networks. There is no strong evidence either for or against this conjecture, in part because sleep has 
been defined, thus far, either behaviorally or at the level of neuronal assemblies. The probability of 
awake-to-sleep transition in a neuronal network (including, possibly, single neurons of that 
network) is increased by the preceding electrochemical activity of these neurons. In this view, sleep 
that is evident behaviorally is an emergent state that coalesces from local sleep foci that might be, 
initially, single neurons. 
Sleep is either counteracted or facilitated by specific neuronal circuits that employ 
wakefulness-enhancing neurotransmitters such as orexins and somnogenic (sleep-promoting) 
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compounds such as extracellular adenosine. Viewing sleep as a process initiated in small neuronal 
networks and/or individual neurons suggests that sleep-regulating circuits have been sculpted, on 
evolutionary timescales, by selection pressures to mitigate cognition-perturbing cellular stress, i.e., 
the molecular cause of sleep. Discovery of this cause is expected to account, among other things, for 
sleep’s homeostatic character. Animals deprived of sleep exhibit impaired cognition, increased 
propensity to sleep (sleep drive), and respond to the incurred sleep “debt” through a longer and 
deeper subsequent sleep. For example, humans not only sleep longer after sleep deprivation but also 
spend more time in NREM sleep, particularly in a part of it called deep sleep, characterized by 
slow-wave activity in the electroencephalogram (EEG), by the lowest mean frequency of action 
potentials, and by the slowest brain metabolism, in comparison to other stages of sleep, and to 
wakefulness as well. For reviews of sleep, see Refs. 6,7,10-43. 
Previously suggested functions of sleep include the null hypothesis
44,45
, i.e., the conjecture 
that sleep is a peculiar form of indolence that has little adaptive value. Cogent arguments against 
this possibility were discussed previously
21,46,47
. Other ideas about the functions of sleep are of two 
kinds: (i) molecular-level and metabolic conjectures; (ii) hypotheses with key assumptions at higher 
than molecular levels, e.g., specific alterations in the strength of synaptic connections or other 
modifications of neuronal circuits. 
One molecular-level hypothesis about the function of sleep is that during wakefulness the 
energy charge (a measure of ATP concentration) in the brain becomes sufficiently low to require a 
functionally distinct period, sleep, that restores the energy charge
48
. This conjecture is extant in the 
field, in the absence of a definitive positive or negative evidence. For example, glucose metabolism 
in the brain cortex (but not, for example, in the hippocampus or hypothalamus) is decreased during 
NREM sleep
49
. On the other hand, oxidative phosphorylation is upregulated during sleep 
deprivation, suggesting an increase in ATP production
50
. In addition, there is no convincing 
evidence that neuronal energy gains during sleep are significant enough to be functionally relevant 
(for a recent discussion, see Refs. 51-54). 
It was also suggested that extracellular adenosine is a natural somnogenic compound that 
contributes to the initiation and maintenance of sleep
14,24,48,55,56
. Extracellular adenosine is derived 
in part from intracellular adenosine via equilibrative adenosine transporters. Adenosine is also 
secreted through regulated vesicular exocytosis
57
. Another source of extracellular adenosine is ATP, 
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which can be released from cells either by vesicular exocytosis or through specific transmembrane 
channels, followed by conversion of ATP to adenosine in the extracellular space
57-62
. Adenosine 
facilitates sleep in part through binding to the neuronal G protein-coupled adenosine receptors. 
Recent evidence strongly suggests a role for extracellular adenosine as an endogenous 
somnogen
56,60,63-67
. 
ATP can act as a somnogen not only through its conversion to adenosine but also through 
the binding of extracellular ATP to P2-type transmembrane receptors, a step that leads to the 
release, largely from microglial cells (brain phagocytes), of cytokines that include interleukin-1β 
(IL1β) and tumor necrosis factor-α (TNFα)
59,68,69
. As described below, these and other 
inflammatory cytokines can act as somnogens, indicating a major but incompletely understood 
connection between the immune system and sleep
7,19,32,34,39,70-82
. Another potent endogenous 
somnogen is the PGD2 prostaglandin, which preferentially induces NREM sleep
13,31,83,84
. The 
somnogenic activity of PGD2 is mediated at least in part by the ability of brain-produced PGD2 to 
increase the concentration of extracellular adenosine
13,31,84
.  
Small compounds such as adenosine, ATP, and PGD2, proteins such as inflammatory 
cytokines, and several other endogenous effectors that act as somnogens are a part of the growing 
understanding of specific circuits that initiate, maintain and regulate sleep. However, none of this 
understanding addresses, by itself, the underlying molecular cause and molecular-level function of 
sleep, which remain unknown. 
Non-molecular conjectures about the functions of sleep have in common the concept of 
sleep as a means of modifying synaptic connections in ways that optimize their activities during 
wakefulness. One example of these hypotheses is the suggestion that the function of REM sleep is 
to minimize deleterious modes of interaction among neurons in the cerebral cortex
85,86
. It was also 
proposed that sleep is influenced by prior synaptic use, and functions to alter synaptic connections, 
in part through the local production of somnogenic compounds that include cytokines
87,88
. Another 
conjecture is that sleep acts to downscale the strengths of synaptic connections, so that increases in 
synaptic strength during wakefulness stay below mechanistically infeasible limits
11,29,89-92
. This 
hypothesis is related to the earlier demonstration that the firing by neurons and the strengths of their 
synapses are homeostatically increased or decreased to maintain firing rates within certain 
boundaries
93
. The synaptic downscaling hypothesis posits, in effect, that the previously 
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characterized recalibration of synaptic strengths
93
 does not suffice during wakefulness, and that 
sleep is required for a further downscaling
29
. Studies on a role of sleep in memory and the evidence 
for such a role
94-98
 are also based on non-molecular models, in part because we still don’t know 
what exactly a long-term memory trace is. In sum, even if these plausible non-molecular 
conjectures about sleep are eventually found to be correct in their domains, they would not, by 
themselves, identify the fundamental molecular problem that the function of sleep may have to 
address. “May” in the preceding sentence refers to the still extant possibility that the cause of sleep 
is not reducible to molecular perturbations in individual neurons and may be, instead, an evolved 
response of neuronal assemblies to “high-level” parameters of such networks, as distinguished from 
changes in individual neurons that result from molecular stress during wakefulness.  
In contrast, the (unproven) premise of the present paper is that the fundamental cause of 
sleep originates in individual neurons. Described below is a molecular-level hypothesis about the 
causation and function of sleep, specific predictions of this hypothesis, and new explanations of the 
properties of sleep, including its evolutionary persistence and homeostatic character. 
 
The Fragment Generation Hypothesis 
In considering causes of sleep, it might be helpful to view it as a metacellular (organismal) 
adaptation to a specific cellular stress during wakefulness. Responses to sleep deprivation suggest 
that sleep functions to counteract a cognition-perturbing molecular process that occurs in neurons, 
“builds up” during wakefulness, causes the initiation of sleep, can prolong its duration and intensity, 
and is down-regulated during sleep. If so, and if sleep is an adaptive response to a cellular stress that 
impairs brain circuits, what is the molecular nature of a key perturbation that renders sleep 
necessary? Furthermore, how does sleep deal with this perturbation? There is also an evolutionary 
problem: given the maladaptive dimension of sleep, why was it impossible to eliminate or bypass 
the (unknown) molecular cause of sleep in the course of evolution? Deleterious aspects of sleep 
include a prolonged and fitness-reducing neglect of mating opportunities, and also the combination 
of immobility, eye closure and higher arousal thresholds that results in a decreased vigilance. Save 
for a minority of animals such as adult top predators, a diminished vigilance of a sleeping animal 
usually signifies its increased vulnerability to predation. Because suppression of consciousness 
during sleep contributes to decreased vigilance, this suppression, too, is maladaptive at least 
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behaviorally. Given these downsides of sleep, why not, for example, a quiet wakefulness, instead of 
sleep? 
I suggest that the molecular cause and function of sleep originate in individual neurons and 
stem from increased production of protein fragments during wakefulness. These fragments, a 
multitude of them, are produced in all cells, including neurons, and are transient parts of protein 
complexes that initially contain full-length precursors of fragments (Fig. 1). Specific cleavage sites 
in proteins that give rise to fragments are maintained by positive selection during evolution, because 
many fragments have adaptive (fitness-increasing) functions. At the same time, at least some 
fragments can also perturb brain circuits. As described below, this (previously not considered) 
dichotomy between adaptive and maladaptive aspects of protein fragments can account for the 
evolutionary persistence of sleep. 
Although this paper considers largely intracellular protein fragments, essentially the same 
logic and analogous physiological ramifications also apply to extracellular protein fragments that 
are secreted from cells or produced from extracellular proteins (including extracellular domains of 
transmembrane proteins) by proteases in the extracellular space. 
In comparison to sleep, the state of wakefulness entails, on average, significantly higher 
Ca
2+
 influxes into neurons. These transient fluxes (Ca
2+
 transients) are mediated by Ca
2+
 
channels
99-101
. Activation of specific transmembrane channels increases the levels of Ca
2+
 in the 
nucleus and the cytosol, including the cytosol’s dendritic and axonal spaces
102-107
. Ca
2+
 channels 
reside in the neuron’s plasma membrane, particularly its synaptic regions, and also in intracellular 
membranes of the endoplasmic reticulum (ER), which is present in axons and dendrites as well
99,100
. 
The ER lumen is one site of Ca
2+
 storage, in addition to extracellular space. The plumes 
(microdomains
108,109
) of Ca
2+
 ions entering specific regions of the cytosol are transient under normal 
conditions, owing to the activity of transmembrane pumps/exchangers that return Ca
2+
 to the 
extracellular space and the ER. Despite the transiency of Ca
2+
 microdomains and despite the 
buffering of Ca
2+
 by Ca
2+
-binding proteins such as calmodulin
110
, increased concentrations of Ca
2+
 
inside microdomains suffice for a local activation of calpains. While the cleavages of proteins by 
calpains are the chief proteolytic consequence of Ca
2+
 transients, these fluxes are also capable of 
activating some secretases
111-113
, and caspases as well, in part through activation of the apoptosome 
and inflammasome
114,115
. Many, possibly most neurons contain activated caspases such as caspase-3 
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(an effector caspase) under conditions in which caspase activation and caspase-mediated protein 
cuts are relatively constrained and do not cause cell death. The resulting protein fragments can be 
involved in neuronal remodeling, including changes that underlie memory
116-118
. As described 
below, these fragments may also contribute to the causation of sleep. 
An individual mammalian genome encodes ~15 distinct calpains, including two major ones, 
calpain-1 (µ-calpain) and calpain-2 (m-calpain). Both neurons and glial cells contain these and other 
calpains. To simplify discussion, only Ca
2+
 transients and the resulting local increases of Ca
2+
 are 
cited below as the cause of calpain activation. Note, however, that other calpain regulators, such as 
phospholipids, protein kinases, calpain-binding proteins, and the ability of some calpains to activate 
themselves and other calpains through specific cuts, are also involved in controlling calpains
119-123
, 
thereby shaping the in vivo repertoires of protein fragments generated by these proteases. 
Production of protein fragments takes place on both presynaptic and postsynaptic sides of 
active synapses, throughout axons and dendrites, in the neuronal soma, in glial cells, and in most 
other cells of an organism. Moreover, the maintenance of brain anatomy, including the suppression 
of sprouting in a stable neurite shaft, has been shown to be an active process mediated by the 
proteolytic activity of calpains (particularly calpain-2) throughout dendrites and axons, even in the 
absence of action potentials and accompanying Ca
2+
 transients
124
. In other words, the preservation 
of normal morphologies and connections throughout the nervous system involves a constant 
generation of protein fragments, above and beyond their production during Ca
2+
 transients at active 
synapses. 
Subunits of transmembrane channels and many other proteins are cleaved by Ca
2+
-activated 
calpains and by other nonprocessive proteases. The resulting C-terminal fragments often have 
N-terminal residues that are “destabilizing” in that they can be recognized by the Arg/N-end rule 
pathway, a processive proteolytic system that targets proteins bearing specific N-terminal 
residues
125,126
 [Figs. 1 and 2(A)]. (Ramifications of this fact for the in vivo dynamics of protein 
fragments are discussed below.) Activated calpains have been shown to cleave approximately 100 
different proteins, most of which are present in neurons (Fig. 3). Because calpain substrates were 
identified by nonsystematic means, the number of different proteins in mammalian neurons that are 
cleaved by calpains is certain to be significantly larger than 100. The known substrates of activated 
mammalian caspases are nearly 1,000 different proteins
127-130
 (Fig. 4). Other proteases, including 
Page 8 of 58
John Wiley & Sons
Protein Science
9 
 
secretases, separases, and aminopeptidases, also produce intracellular protein fragments, including 
fragments that bear destabilizing N-terminal residues (Fig. 5). In addition, proteins that reside in or 
move through secretory compartments such as the ER can be cleaved by compartment-specific 
proteases. Most fragments generated by nonprocessive proteases are protein-size molecules 
(Figs. 3-6). They are degraded processively to short peptides at varying rates, often after delays, by 
specific branches of the N-end rule pathway (Figs. 1 and 2), by other pathways of the ubiquitin 
system, and through the autophagy-mediated lysosomal proteolysis as well. 
In the proposed concept, termed the fragment generation (FG) hypothesis, sleep is a state 
that originates in individual neurons and involves a decreased production of protein fragments 
(owing in part to lower Ca
2+
 transients) as well as increased activities of fragment-destroying 
proteolytic pathways. These changes would facilitate the elimination of fragments and the 
remodeling of protein complexes in which the fragments were produced and transiently resided. 
The FG hypothesis leads to mechanistic explanations of specific properties of sleep, including its 
evolutionary persistence and homeostatic character (a longer sleep after sleep deprivation), as well 
as a broad variation of sleep duration and other features among different species. 
 
Monitoring Protein Fragments and Reacting to Their Accumulation 
If the increased generation of protein fragments during wakefulness and specific 
cognition-perturbing effects of this process underlie the causation of sleep, the individual neurons 
and circuits that regulate sleep must be able to “sense” either changes in the concentrations of 
fragments or consequences of these changes. One idea is that some proteins have acquired, during 
evolution, specific cleavage sites for yielding protease-generated fragments that function as 
somnogenic proteins. Such sensor-effector proteins and their fragments would allow systems that 
regulate sleep to gauge the increased production of many different fragments during wakefulness 
and to react by increasing the levels of somnogenic compounds, for example, extracellular 
adenosine, ATP or PGD2. These compounds, acting autocrinally and paracrinally (on cells that 
release them and on nearby cells), would promote a switch to a distinct state, sleep, whose salient 
features, according to the FG hypothesis, include lower Ca
2+
 transients, a slower production of 
fragments, and upregulated pathways that destroy fragments and remodel protein complexes in 
which the fragments resided.  
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PANX1, a transmembrane protein and a conditional ATP release channel, is one plausible 
example of what the postulated sensor-effector protein may be, in the framework of the FG 
hypothesis. The level of extracellular ATP (a somnogenic compound; see Introduction) could be 
upregulated, for example, through the activity of the caspase-generated fragment of PANX1 
(Fig. 7). Specifically, the ability of PANX1 to function as an ATP release channel has been shown 
to be greatly increased by its caspase-mediated truncation
131,132
. As mentioned above, caspases, 
including effector caspases, can be active in non-apoptotic neurons
116-118,133,134
. It is unknown, at 
present, whether activated calpains can also cleave and activate PANX1 and/or several other, 
related transmembrane proteins that function as ATP release channels. For a further discussion of 
connections between ATP/cytokine pathways and protein fragments, see the FG Hypothesis and the 
Somnogenic Activity of Cytokines section below. 
Another possible mechanism for coupling a rising concentration of fragments to the activity 
of sleep-regulating circuits involves E3 ubiquitin ligases of the Arg/N-end rule pathway, called 
N-recognins. They bind to destabilizing N-terminal residues of protein fragments [Fig. 2(A)]. A 
fragment of a cleaved subunit of a protein complex may remain associated with the rest of a 
complex, owing to partially retained interactions within the complex. These interactions may 
include an association between the N-terminal and C-terminal fragments of a cleaved, 
complex-bound protein subunit. Examples of nondissociating or slowly dissociating cleaved protein 
complexes, including transmembrane channels, specific enzymes, and transcriptional regulators, are 
described in Refs. 135-139. The ability of the Arg/N-end rule pathway to destroy a C-terminal 
fragment that is embedded in a protein complex would be constrained by the fragment’s 
noncovalent interactions within the complex. If so, a pool of slowly dissociating fragments that bear 
sterically accessible destabilizing N-terminal residues may act as a physical sink for N-recognins, 
thereby decreasing the ability of the Arg/N-end rule pathway to target other Arg/N-end rule 
substrates. 
Now suppose that a positive regulator of somnogens is a naturally short-lived protein 
substrate of the Arg/N-end rule pathway. If so, the rise of protease-generated fragments that can 
interact with N-recognins but cannot be eliminated by them efficaciously enough would titrate 
available N-recognins. As a result, the normally short-lived regulator would be partially stabilized, 
increasing in steady-state levels and thereby upregulating the levels of a cognate somnogen as well. 
Page 10 of 58
John Wiley & Sons
Protein Science
11 
 
Given large distances between the soma and distal regions of axons and dendrites, a transient 
inhibition of the Arg/N-end rule pathway by this mechanism may occur locally rather than 
cell-wide. NTAN1 mRNA, which encodes Nt
N
-amidase, a component of the Arg/N-end rule 
pathway [Fig. 2(A)], has been detected in axons
140
, suggesting that both Nt
N
-amidase and other 
components of the pathway can be produced not only in the neuronal soma but in axons and 
dendrites as well, through spatially localized translation of specific mRNAs. 
A transient trapping/inhibition of specific ubiquitin ligases by protein fragments that are 
embedded in protein complexes may involve other proteolytic pathways as well, for instance those 
that can target N-terminal (as distinguished from C-terminal) protein fragments. One example of 
such systems is the Ac/N-end rule pathway, which targets N
α
-terminally acetylated (Nt-acetylated) 
proteins [Fig. 2(B)]. To address experimentally these, already expected complexities, it would be 
essential to develop methods for measuring the in vivo activity of the Arg/N-end rule pathway and 
analogous proteolytic systems specifically in axons and dendrites. 
 
Protein Fragments, Their Generation In Spite of Deleterious Effects, and the 
Evolutionary Persistence of Sleep 
The FG hypothesis posits that proteolytic cleavages and the resultant protein fragments have 
both deleterious effects and adaptive (fitness-increasing) functions. For example, a specific 
cleavage-generated protein fragment can be deleterious while the other fragment, produced by the 
same cut, can have an adaptive function. Thus, remarkably, a cleavage of a protein may have both 
adaptive and harmful consequences at the same time. This is an important but previously not 
considered feature of in vivo proteolytic cuts. This property of cleavages, in addition to other 
dichotomies that involve protein fragments, can account for the observed evolutionary stability of 
specific cleavage sites in proteins (Fig. 6), because at least one of two fragments formed by a 
cleavage would have an adaptive function. 
For example, calpain-mediated cleavage of a protein may act as a timing device that “tags” a 
transient event such as a Ca
2+
 microdomain by generating a cleaved protein complex that may be 
spatially confined to a specific dendritic spine. Such events were proposed to involve spectrin as a 
cytoskeletal protein whose cleavage by calpains at active synapses might contribute to memory 
processes
141
. Many other proteins can also be cleaved by activated calpains (Fig. 3). Some of these 
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cleavages and the resulting protein fragments may be a part of memory processes. According to the 
FG hypothesis, deleterious aspects of these and other protein fragments underlie the causation of 
sleep. 
The necessity of apoptosis and other forms of programmed cell death in multicellular 
eukaryotes is one reason for the acquisition and retention of caspase cleavage sites (and of some 
calpain cleavage sites) in proteins during evolution. An example of fitness costs imposed by calpain 
cleavage sites are excessive calpain-mediated cleavages of neuronal proteins under conditions of 
excitotoxicity, for example, upon sustained increases of extracellular glutamate (which induces Ca
2+
 
transients) in brain regions affected by stroke. Note, however, that similar cleavages of neuronal and 
glial intracellular proteins take place during normal wakefulness as well (Fig. 3), but at frequencies 
that are too low for irreversible cytotoxic effects. Nevertheless, these lower frequencies of cleavages 
are still high enough, according to the FG hypothesis, for a gradual perturbation of cognition and 
for eliciting responses by circuits that regulate sleep. With most calpain substrates cited in Fig. 3, a 
rough estimate is that less than 20% of a substrate is cleaved at steady-state during normal 
wakefulness. Given low percentages of cleaved protein complexes, their (postulated) ability to 
perturb cognition may stem from gain-of-function effects, either by an initially cleaved complex 
that retains both products of a cut, or by an un-remodeled complex, after the elimination of at least 
one fragment. 
A protein fragment may be deleterious by not dissociating rapidly enough from a protein 
complex in which the fragment had been produced, or by acting as a perturbant in its free 
(dissociated) state. For example, a free fragment may form toxic oligomers or larger aggregates. A 
deleterious effect of a fragment may be accompanied by an independently present adaptive function 
of the same fragment, for example, by its necessity for a role that cannot be performed by the 
full-length precursor protein. Another possibility, mentioned above, is that one of two 
cleavage-generated protein fragments is deleterious while the other one has an adaptive function.  
If a maladaptive aspect of a protein cleavage is not accompanied by a different, 
fitness-increasing effect of this event, there would be a selection pressure to eliminate the cleavage 
site. Calpain cleavage sites encompass ~10 residues, involve both conformational and sequence 
determinants, and can be impaired or inactivated by missense mutations
119-123,142
. Caspase cleavage 
sites are simpler and can be readily inactivated by missense mutations
129,143
. Given the ease of 
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elimination, on evolutionary timescales, of deleterious cleavage sites in neuronal and other proteins, 
it is striking, and most telling, that both calpain and caspase cleavage sites are highly conserved at 
least among vertebrate proteins (Fig. 6). 
Also telling, in a different and independent way, is the evolutionary pattern of P1’ residues 
in these cleavage sites. (P1’ residues become N-terminal after a cleavage.) Specifically, the exact 
identity of a P1’ residue is not always conserved during evolution. Remarkably, however, the 
destabilizing nature of a P1’ residue, i.e., its ability, once it becomes N-terminal, to be recognized 
by the Arg/N-end rule pathway [Fig. 2(A)], is virtually always conserved (Fig. 6). This evolutionary 
pattern of P1’ residues in the precursors of natural protein fragments strongly suggests that the 
ability of C-terminal fragments to be targeted as substrates of the Arg/N-end rule pathway is a 
positively selected property of these fragments.  
A caveat to this view of evolution of the P1’ residues is that their conservation in a specific 
cleavage site often occurs in a sequence context that is also conserved, at least among vertebrates 
[Fig. 6(A, E, F), and data not shown]. An alternative interpretation, in such cases, is that the 
observed conservation of a P1’ residue stems from a low tolerance for sequence alterations 
throughout the cleavage site (for example, because this site is a critical part of a structure required 
for a protein’s function), as distinguished from selection that acts to retain destabilizing activity of a 
P1’ residue. In such cases (and also, strictly speaking, in all cases that involve P1’ residues), the 
hypothesis of positive selection for destabilizing P1’ residues must be verified by causative 
(genetic) tests that examine fitness changes of organisms in which a wild-type destabilizing P1’ 
residue in a precursor of C-terminal fragment has been replaced by a residue that is not recognized 
by the Arg/N-end rule pathway [Fig. 2(A)]. 
Based on this experimental background (Figs. 1-6), the FG hypothesis posits a specific 
explanation for the observed evolutionary persistence of sleep, despite its maladaptive properties 
cited above. Specifically, the retention, through positive selection, of cleavage sites in proteins and 
the resulting evolutionary persistence of protease-generated fragments compel the existence of sleep 
as well, because sleep counteracts deleterious aspects of protein fragments. As discussed below, the 
FG hypothesis also leads to new explanations of the documented malleability of sleep, including its 
striking variations among different animals. In the framework of this hypothesis, the rates of 
generation of specific protein fragments by nonprocessive proteases, the rates of subsequent 
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degradation of fragments to short peptides, and the rates of remodeling of protein complexes in 
which these fragments initially resided (Fig. 1) are independently tunable parameters that can be 
altered in individual neurons and other cells.  
Consequently, variations in the rates of initial protein cleavages, in the rates of fragments’ 
processive degradation, and in the rates of subsequent protein remodeling that would be favored by 
the ecology of an organismal lineage can be selected and optimized on evolutionary timescales. The 
results of such adjustments may underlie and explain many differences in homeostatic aspects and 
other properties of sleep among different animal species. For example, the duration of sleep in 
mammals varies from ~4 hr in mountain goats to ~16 hr in hedgehogs. The fact that sleep is 
universal at least among vertebrates and takes hours rather than minutes per day even among 
shortest-sleeping animals implies that a massive decrease or elimination of sleep during evolution 
was impossible cost-wise. According to the FG hypothesis, the cost of sleep reduction stems from 
the necessity of counteracting, through sleep, specific deleterious aspects of (positively selected) 
protein fragments. If so, one task at hand is to identify protein fragments that are particularly 
relevant to sleep causation, as well as specific mechanisms of fragment-mediated deleterious effects 
that occur in the absence of sleep.  
 
Examples of Proteolytic Cuts That Can Be Both Beneficial and Deleterious 
 
Proapoptotic protein fragments 
A recent study by our laboratory described the discovery that the Arg/N-end rule pathway is 
a repressor of apoptosis, through the ability of this pathway to destroy caspase- or calpain-generated 
proapoptotic protein fragments
126
. Such fragments are defined, operationally, as those that increase 
the probability of apoptosis compared with full-length precursors of fragments. Metabolic 
stabilization of the proapoptotic, normally short-lived Cys-RIPK1 fragment of the RIPK1 kinase 
[Fig. 4(#1) and Fig. 6(A)] through the mutational conversion of its destabilizing N-terminal Cys to 
Val (which is not recognized by the Arg/N-end rule pathway) was found to elevate the fragment’s 
in vivo levels and thereby to greatly increase its (intrinsic) proapoptotic activity
126
. Abnormally high 
proapoptotic activity of a naturally produced proapoptotic fragment such as Cys-RIPK1 would be 
expected to be maladaptive, strongly suggesting (though not proving) that the presence and 
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evolutionary conservation of a destabilizing N-terminal residue in Cys-RIPK1 [Fig. 4(#1) and 
Fig. 6(A)] stems from a positive selection for such a residue.  
Ten proapoptotic fragments characterized as short-lived N-end rule substrates in the cited 
study
126
 [Fig. 3(#16, #17) and Fig. 4(#1-8)] are likely to be produced, at low but non-zero yields, in 
non-apoptotic cells as well. It remains to be determined whether any one among these C-terminal 
fragments (and/or their N-terminal counterparts) can be beneficial under conditions distinct from 
apoptosis. These ten fragments (at least twenty with N-terminal fragments as well) are the tip of the 
iceberg vis-à-vis the total number of different fragments (possibly hundreds of them) that are likely 
to be relevant to the FG hypothesis (Figs. 3-6).  
Effects of inflammatory cytokines such as TNFα include the activation of caspases in target 
cells (Ref. 126 and Refs. therein). I suggest that the somnogenic activity of TNFα and analogous 
cytokines (see Introduction) is mediated in part by activation of caspases in neurons. This activation 
would yield a variety of protein fragments, including the previously characterized proapoptotic 
fragments that are targeted for degradation by the Arg/N-end rule pathway
126
 [Fig. 4(#1-8)]. In this 
view, increasing concentrations of extracellular TNFα and other somnogenic cytokines in the brain 
during wakefulness generate activated caspases and specific intracellular protein fragments at levels 
that do not cause apoptosis but result, instead, in higher probabilities of awake-to-sleep transitions 
in individual neurons and neuronal networks (see the FG Hypothesis and the Somnogenic Activity 
of Cytokines section below). 
 
A fragment of cohesin 
Another example of functional dichotomies in proteolytic cuts is a subunit of cohesin
144
. 
Cohesin rings encircle two replicated daughter chromatids and thereby maintain, through a 
topological confinement, the cohesion of chromatids until mitosis
145-147
. An endoprotease called 
separase is activated during mitosis and cleaves the Scc1/Rad21 (kleisin) subunit, thereby opening 
the ring of cohesin and making chromatid separation possible. In the yeast Saccharomyces 
cerevisiae, the C-terminal fragment of separase-cleaved Scc1/Rad21 bears N-terminal Arg, a 
destabilizing residue [Fig. 2(A)]. This fragment, which remains associated with cohesin complex, is 
dislodged and degraded by the Arg/N-end rule pathway
144
. The rest of cohesin complex is 
apparently spared, owing to the subunit selectivity of the Arg/N-end rule pathway
125,148-150
. 
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The identity of a residue at the N-terminus of a C-terminal fragment of Scc1/Rad21 varies in 
a tellingly constrained manner. Specifically, this residue is Arg in the budding yeast S. cerevisiae, 
Asn in the fission yeast S. pombe, Cys in D. melanogaster, and Glu in mammals. All of these 
N-terminal residues are destabilizing in the Arg/N-end rule pathway
144,151
 [Fig. 2(A)]. This 
evolutionary constraint indicates the necessity of “proactive” elimination of the C-terminal fragment 
of Scc1/Rad21. The removal of this fragment leads to the eventual reconstitution (remodeling) of 
cohesin through incorporation of the uncleaved Scc1/Rad21 subunit
144
.  
In ubr1∆ S. cerevisiae, which lack the Arg/N-end rule pathway, the normally short-lived 
C-terminal fragment of Scc1/Rad21 is a long-lived protein
144
. In this setting, the C-terminal 
fragment can apparently still dissociate (or is displaced) from the rest of cleaved oligomeric cohesin 
in vivo at a rate that is compatible with the functioning of cohesin pathways. However, this 
degradation-independent route is inefficient enough to cause a striking (~1,000-fold) increase in the 
frequency of chromosome loss in ubr1∆ cells
144
. Similar genomic instability is observed in ate1∆ 
mouse cells, which lack R-transferase and therefore lack the arginylation branch of the Arg/N-end 
rule pathway [Fig. 2(A)]. R-transferase is required for the degradation of the C-terminal fragment of 
the mammalian Scc1/Rad21 subunit, as this fragment bears N-terminal Glu, a secondary 
destabilizing residue
125,151
 [Fig. 2(A)] (J. Zhou, C. Brower, D. Pati and A.V., unpublished data). 
Viewed together, the separase-mediated cleavage of Scc1/Rad21, the necessity of this 
cleavage for chromosome segregation, and the overtly deleterious effect of the resulting (cohesin-
bound) C-terminal Scc1/Rad21 fragment in the absence of the Arg/N-end rule pathway
125,144
 are an 
illustration of some concepts that underlie the FG hypothesis. 
 
The amyloid-β (Aβ) protein fragment 
Remarkably, an example of a deleterious protein fragment that accumulates in the brain, is 
down-regulated during sleep, and is augmented during sleep deprivation, is already known
152
. The 
42-residue amyloid-β (Aβ) protein fragment is produced through cleavages, by proteases of the 
secretase family, from the transmembrane amyloid precursor protein (APP). Upon its formation at 
the cell’s plasma membrane, Aβ becomes largely extracellular but can also be found in the 
cytoplasm. Aβ forms toxic oligomers and larger aggregates. Its accumulation in the brain is among 
the causes of Alzheimer’s disease. At the same time, significantly lower concentrations of Aβ might 
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have beneficial effects. For example, Aβ may function as an antimicrobial peptide
153
. The largely 
extracellular localization of Aβ is consistent with the FG hypothesis, because essentially the same 
logic and analogous physiological ramifications would apply to cognition-perturbing intracellular 
and extracellular protein fragments. It should be noted that the study that described the circadian 
and sleep-deprivation pattern of Aβ expression
152
 did not consider the possibility, proposed by the 
FG hypothesis, that such a pattern may be a manifestation of the far more general phenomenon in 
which a multitude of different protein fragments are generated in the brain during wakefulness and 
are, collectively, the molecular cause of sleep.  
 
Fragments of Neuronal Proteins As N-End Rule Substrates 
More than 50% of the previously mapped C-terminal fragments of calpain-cleaved proteins 
bear N-terminal residues that can be targeted by the Arg/N-end rule pathway (Fig. 3). The N-end 
rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. Regulated 
degradation of specific proteins by the N-end rule pathway mediates a multitude of biological 
functions (Fig. 2 and its legend). The N-end rule pathway polyubiquitylates proteins that contain 
specific degradation signals (degrons), either internal or N-terminal (N-degrons). The main 
determinant of an N-degron is a destabilizing N-terminal residue of a protein (Fig. 2). The N-end 
rule pathway consists of two branches, the Ac/N-end rule and the Arg/N-end rule pathways (for 
reviews, see Refs. 125,154-157). The Ac/N-end rule pathway, described below, recognizes proteins 
with Nt-acetylated N-terminal residues
125,158
. The Arg/N-end rule pathway targets specific 
unacetylated N-terminal residues. The primary destabilizing N-terminal residues Arg, Lys, His, 
Leu, Phe, Tyr, Trp, and Ile are directly recognized by N-recognins (E3 ubiquitin ligases of the 
N-end rule pathway), whereas N-terminal Asp, Glu, Asn, Gln, and Cys function as destabilizing 
residues through their preliminary enzymatic modifications [Figs. 1 and 2(A)]. 
Altogether, 71 C-terminal fragments of specific cleaved proteins that are either identified or 
predicted Arg/N-end rule substrates are described in Figs. 3-6. This list, based on extensive 
literature searches, contains a majority of mapped calpain substrates (34 proteins; Fig. 3); a small 
subset of mapped caspase substrates (30 proteins; Fig. 4); and a few examples of proteins that are 
cleaved in vivo by other nonprocessive proteases (Fig. 5). The total number of fragments is more 
than twice the cited number, given the production of N-terminal/C-terminal pairs of fragments and 
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frequent multiple cleavages of a full-length protein. Among the proteins that are cleaved by calpains 
and yield predicted Arg/N-end rule substrates are ligand- or voltage-regulated transmembrane 
proteins that mediate or control Ca
2+
 transients [Fig. 3(#1-4, #6)]; (#6)]; specific enzymes 
[Fig. 3(#25, #29)]; transcriptional regulators [Fig. 3(#19)]; and many other proteins (Fig. 3). 
Although the discussion was confined, thus far, to C-terminal fragments of protein 
precursors, many N-terminal fragments are also likely to be N-end rule substrates, owing to the 
Ac/N-end rule pathway, the second branch of the N-end rule pathway [Fig. 2(B)]. More than 80% 
of human proteins are Nt-acetylated as nascent polypeptide chains by ribosome-associated 
Nt-acetylases
159
. In 2010, it was discovered that the Nt-acetylated residues of cellular proteins act as 
specific degradation signals, termed Ac/N-degrons, to distinguish them from N-degrons of the 
Arg/N-end rule pathway, which recognizes specific unacetylated N-terminal residues
158
 (Fig. 2). 
The new field of the Ac/N-end rule pathway is just beginning to be explored. 
As suggested previously
158
, a key feature of Ac/N-degrons is their conditionality, in that 
usually a protein would not be targeted for degradation via its Ac/N-degron, save for a brief interval 
between the cotranslational formation of an Ac/N-degron in a nascent protein and the subsequent 
incorporation (sequestration) of this protein in a cognate oligomeric complex. What might be the 
consequence of a proteolytic cut in a protein subunit for the metabolic fate of a resulting N-terminal 
fragment? Some N-terminal fragments may be sufficiently destabilized conformationally to expose, 
and thereby to re-activate, their Ac/N-degrons (Fig. 1). Other N-terminal fragments of cleaved 
proteins may remain associated with their protein complexes and remain either inaccessible or at 
most intermittently (stochastically) accessible to the Ac/N-end rule pathway. In sum, the functional 
effects and metabolic fates of N-terminal fragments in cleaved protein complexes are at least as 
relevant to the FG hypothesis as the effects and fates of C-terminal fragments. 
Either dissociation of fragments from protein complexes or the subsequent processive 
degradation of fragments may be slow enough to result in accumulation of specific fragments 
during wakefulness. (For many fragments, the dissociation and degradation steps would be 
mechanistically coupled.) According to the FG hypothesis, at least some of these fragments and/or 
un-remodeled protein complexes in which the fragments transiently resided can perturb cognition. 
As mentioned above, the rate at which a newly generated fragment becomes susceptible to the 
targeting and processive degradation may be limited by the rate of its dissociation from a protein 
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complex, owing to noncovalent interactions within the complex and also, for example, to an 
intermittent (stochastic) steric accessibility of a fragment’s degradation signal. 
 
Relationship of Protein Fragments to Other Somnogens 
 
The FG hypothesis and somnogenic activity of cytokines 
Positive regulation of sleep involves both small compounds (adenosine, ATP, PGD2, nitric 
oxide, oleamide) and protein-size effectors, including inflammatory cytokines such as TNFα and 
IL1β, and other hormones/growth factors such as epidermal growth factor (EGF), growth hormone 
releasing hormone (GHRH), prolactin, nerve growth factor (NGF), and brain-derived neurotrophic 
factor (BDNF) (reviewed in Refs. 7,19,70,71). Inflammatory cytokines of the immune system are 
produced both peripherally and in the brain, and have somnogenic activity. (Hence the common 
observation of increased sleepiness during a bout of infectious disease.) Bacterial 
lipopolysaccharide (LPS) and other components of microorganisms that activate the innate immune 
system are also somnogenic
34,75
. LPS and analogous bacterial compounds act as somnogens owing 
largely to their ability to upregulate somnogenic cytokines. A prolonged sleep deprivation increases 
susceptibility to infection in both humans and rodents
32,39,76-78
. In healthy humans, the levels of IL1β 
in blood plasma are highest at the onset of sleep
19,79
.  
This and other evidence, including circadian control of the production of somnogenic 
cytokines, indicates their involvement in physiological sleep regulation. Activated processing and 
release of cytokines by microglia (brain phagocytes) is caused in part by rising levels of 
extracellular ATP during wakefulness. ATP is released from cells by vesicular exocytosis and 
through transmembrane channels (ATP release channels) such as PANX1, which can be activated 
by Ca
2+
 transients and by other effectors. Acting autocrinally and paracrinally, the extracellular 
ATP binds to P2-type receptors such as P2X7, which are present largely on microglial cells. 
Through mechanisms that remain to be clearly understood, this binding results in proteolytic 
processing and release of inflammatory cytokines
7,19,59,70,71
. Given this understanding, how might an 
increased generation of protein fragments during wakefulness – the proposed molecular cause of 
sleep – interact with ATP/cytokine pathways?  
First, as suggested above (Fig. 7) (see Monitoring Protein Fragments and Reacting to Their 
Accumulation section), an increased generation of protein fragments during wakefulness may be 
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conveyed to sleep-regulating circuits through cleavages of (postulated) sensor-effector proteins. 
PANX1, a conditional ATP release channel, might be one such protein. PANX1 can be cleaved by 
caspases, a truncation that has been shown to activate PANX1 as an ATP release channel
131,132
. The 
proposed PANX1-mediated mechanism is but one of several possible ways to link augmented 
generation of protein fragments during wakefulness to the ATP/cytokine system that contributes to 
sleep initiation. Note that the effects of inflammatory cytokines such as TNFα include the activation 
of caspases in target cells
126
. As suggested above (see the Proapoptotic Protein Fragments section), 
the somnogenic activity of TNFα and analogous cytokines may be mediated in part by caspases. 
Their activation in neurons, while remaining below apoptotic levels, results in augmented 
generation of specific protein fragments and therefore, according to the FG hypothesis, in higher 
probabilities of awake-to-sleep transitions in individual neurons and neuronal networks.  
Second, a somnogenic response of neurons to cytokines may be modulated by the levels of 
specific protein fragments that neurons contain at the time of their exposure to cytokines. As a 
result, at a given concentration of extracellular cytokines some neurons may undergo awake-to-
sleep transitions, whereas other nearby neurons may not. In this model, the levels of specific protein 
fragments in a set of neurons would be increased by their recent electrochemical activity, owing to 
Ca
2+
 transients. The resulting concentrations of fragments would determine the probability of 
awake-to-sleep transitions, in a neuron or a neuronal assembly, in response to a given level of 
extracellular cytokines. Being both the molecular cause of sleep and a function of Ca
2+
 transients, 
the generation of protein fragments can track electrochemical activity of neurons and convey the 
level of activity-generated stress to ATP/cytokine pathways and other somnogenic systems. 
Third, it has not been considered so far that although inflammatory cytokines and other 
protein-size somnogens signal through distinct cell surface receptors, these diverse effectors have a 
feature in common: they augment, directly or indirectly, calpain-activating Ca
2+
 transients in both 
neurons and glial cells
160-167
. In addition, some somnogenic effectors can activate calpains 
independently of Ca
2+
 transients. For example, EGF can activate calpain-2 by upregulating kinases 
that phosphorylate and thereby activate this calpain
168
. I suggest that these properties of protein-size 
somnogens and the resulting activation of calpains and other nonprocessive proteases such as 
caspases, comprise a specific somnogenic mechanism. In other words, it is proposed that 
inflammatory cytokines and analogous extracellular effectors act as somnogens at least in part 
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because their binding to cognate receptors accelerates calpain-mediated and caspase-mediated 
generation of protein fragments. As suggested above, it is the concentrations of specific protein 
fragments in neurons that may determine the probabilities of awake-to-sleep transitions in response 
to a given level of extracellular cytokines. If so, the ability of cytokines, in this model, to upregulate 
the very process (generation of fragments) that contributes to their somnogenic activity would result 
in a positive feedback loop, a verifiable possibility. 
Although the overall model is sufficiently specific to allow experimental testing, it is 
under-determined, for example, in regard to identities of protein fragments that are functionally 
critical for responses to specific cytokines or other somnogenic effectors. On the (unproven) 
assumption that the FG hypothesis is correct at least in outline, one can ask, for instance, whether 
calpain-mediated cleavages of specific Ca
2+
 channels [Fig. 3(#2, #4, #6)] are more important for 
determining the probability of awake-to-sleep transition in response to a somnogen than the 
cleavages of other neuronal proteins, such as those described in Fig. 3. Is there, in fact, a specific 
subset of protease-generated fragments (and their parental protein complexes) that largely 
determines the sensitivity of a neuron (or a neuronal assembly) to a given somnogen? These are 
some of experimentally addressable questions in this domain of the FG hypothesis.  
 
Ethanol-induced sleep and Ca2+ transients 
Ethanol readily crosses the blood-brain barrier and at sufficiently high doses acts as a 
somnogen. The main molecular mechanism through which ethanol exerts its somnogenic effect is 
unclear. Although biochemical impacts of ethanol on the brain are many and varied, the available 
evidence indicates that one major effect of ethanol is to increase Ca
2+
 transients in neurons and 
astrocytes
169-171
. Higher Ca
2+
 transients promote the activation of calpains and other nonprocessive 
proteases. Hence the prediction, by the FG hypothesis, that a major somnogenic effect of ethanol 
may be its ability to increase the generation of protein fragments in neurons and other brain cells. In 
the 1970s, several studies showed that ethanol-induced sleep in mice can be strikingly prolonged by 
injections of either Ca
2+
 alone or Ca
2+
 and its ionophore
1-3
. (Sleep was measured by the duration of 
unconsciousness and the loss of righting reflex after intraperitoneal injection of ethanol.) For 
example, at a dose of ethanol that resulted in a sleep for ~68 min, an intracerebroventricular 
injection of CaCl2 (20 µmoles/kg) 30 min before ethanol injection resulted in a continuous sleep for 
~234 min, a nearly 3.5-fold increase compared to the control injection of buffer alone
1
. Similar 
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effects were observed upon injections of a lower amount of CaCl2 in the presence of a Ca
2+
 
ionophore
1-3
. These results were never interpreted in connection to protein fragments or the function 
of sleep. Moreover, these studies from three decades ago seem to be no longer discussed in the 
current literature about mechanisms of sleep. Note, however, that these results, obtained for 
unrelated reasons
1-3
, may be accounted for by the FG hypothesis, in that an increase in Ca
2+
 
transients (which augment the levels of activated calpains and other nonprocessive proteases) is 
predicted to be somnogenic. Further exploration of ethanol/calcium-induced sleep and extensions of 
this approach to mutants in the mouse Arg/N-end rule pathway
126,172
, with measurements of specific 
protein fragments in the brain, are a promising way to explore the cause of sleep vis-á-vis the FG 
hypothesis.  
 
Protein Fragments and Specific Properties of Sleep 
 
Sleep deprivation and homeostatic aspects of sleep 
The FG hypothesis can account, in general terms so far, for homeostatic aspects of sleep. 
Specifically, a prolongation of wakefulness, i.e., sleep deprivation would be expected to generate a 
larger load of undestroyed protein fragments and un-remodeled protein complexes. The result, 
according to the FG hypothesis, would be increasingly perturbed cognition, in agreement with 
experimental evidence about sleep deprivation. Given higher than normal levels of protein 
fragments and un-remodeled protein complexes by the end of sleep deprivation, adjustments of 
those levels during subsequent sleep would be expected to take a longer time, resulting in a longer 
sleep, in agreement with known effects of sleep deprivation.  
 
Suppression of sleep and unihemispheric sleep 
Described below are variations of sleep that offer additional opportunities to address 
predictions of the FG hypothesis. Studies of Danio rerio fishes (zebrafishes) identified a specific 
dichotomy in their responses to sleep deprivation. Adult zebrafishes are diurnal, being active during 
the day and less active at night, with prolonged episodes of sleep, defined behaviorally
15,173,174
. If 
adult zebrafishes were sleep-deprived, in darkness, through repetitive electric stimulation and 
thereafter observed during an extended period of darkness, they exhibited prolonged sleep, as would 
be expected of responses to sleep deprivation in mammals. However, this compensatory 
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prolongation of sleep after sleep deprivation was not observed if sleep-deprived zebrafishes were 
released into light
173
. Moreover, sleep-deprived zebrafishes that were kept under constant light 
conditions exhibited little sleep to begin with, despite the preceding sleep deprivation in darkness
173
. 
A similar and nearly complete suppression of sleep was also observed with zebrafishes kept under 
constant light for at least 3 days. Sleep reappeared and progressively increased by 8 days in the 
presence of light. No significant rebound sleep was observed afterwards in darkness, despite the 
(formally defined) sleep deprivation under constant-light conditions
173
.  
In the framework of the FG hypothesis, these, currently unexplained, sleep patterns in 
zebrafishes may be accounted for by different rates of reactions (under different conditions of sleep 
deprivation described above) that mediate the generation or degradation of specific protein 
fragments and the remodeling of protein complexes that initially contained these fragments. 
Addressing these issues experimentally with zebrafishes can involve, at first, quantitative 
comparisons of the levels of protease-generated protein fragments, either of a kind described in 
Figs. 3-6 or of any kind, using proteome-scale, mass spectrometry-based techniques. For example, 
one verifiable possibility is that long-term illumination of zebrafishes may upregulate their 
intracellular fragment-degrading pathways, including, possibly, the N-end rule pathway, so that 
specific (relevant to sleep causation) protein fragments are destroyed faster than in the dark. As a 
result, the levels of these fragments under constant light would be predicted to be, at least initially, 
lower than they would be during the diurnal pattern of alternating light and darkness, resulting in a 
low sleep drive in the light, despite the lack of sleep. Specific causative studies, including genetic 
approaches (they are feasible with zebrafishes), would be essential as well, to verify and deepen 
FG-based mechanistic interpretations. 
Sleep in cetaceans (dolphins and whales) and in some pinnipeds (walrus, sea lions, fur seals, 
eared seals, and earless seals) has a property called the unihemispheric slow wave (USW) sleep. 
This is a form of NREM sleep in which the state of being asleep alternates between two brain 
hemispheres and is accompanied by only one closed eye at a time, the one that is contralateral to 
(and is innervated by) the sleeping hemisphere
27
. The likely adaptive nature of USW sleep stems 
from the ability of, for example, a fur seal to monitor its immediate environment for predators and 
conspecifics using a single open eye, to continue to swim, and to continue staying “halfway” alert 
most of the time. Among terrestrial animals, only birds exhibit aspects of unihemispheric sleep, but 
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not as pronounced as in cetaceans
27,175
. The USW sleep has evolved in marine mammals 
presumably because it is particularly adaptive in aquatic settings, as the terrestrial environment can 
provide an animal with a measure of protection during sleep, for example, in burrows and trees. In 
addition, vulnerable grazing ungulates, such as antelopes, tend to sleep in herds, in which there are 
always some animals (sentinels) that are not asleep
175
. Strikingly, the NREM sleep in fur seals can 
be of two kinds. On land, seals exhibit, most of the time, a bilaterally symmetrical slow wave 
(BSW) sleep, similar to NREM sleep in terrestrial mammals. In contrast, when a fur seal sleeps in 
water, its EEG patterns indicate a unihemispheric slow wave (USW) sleep, as in whales and 
dolphins
27,176
.  
This switch from BSW sleep on land to USW sleep in water may be an opportunity to 
address a prediction of the FG hypothesis. In the BSW sleep (on land), when both hemispheres 
sleep at the same time, specific (e.g., relevant to sleep causation) protein fragments in the two 
hemispheres of the seal’s brain would be expected to be present at equal levels, irrespective of the 
timing of brain analyses during sleep-wakefulness cycles. In contrast, if it is the destruction of 
protein fragments that does not keep pace with fragments’ accumulation during wakefulness, the 
FG hypothesis predicts that during the USW sleep (in water), the sleeping brain hemisphere of a fur 
seal would contain lower levels of these fragments than the awake hemisphere of the same brain. 
This is a verifiable proposition. Its upside is that a negative result (the absence of significant 
differences between the levels of assayed protein fragments in a sleeping versus awake hemisphere 
of a seal or a bird) would make the FG hypothesis less likely to be correct. A downside of such 
comparisons is their correlational (non-causative) nature.  
 
Protein fragments and the size of a nervous system 
Generation of protein fragments and the accompanying production of protein complexes that 
have to be remodeled after fragments’ removal are cell-autonomous processes. Therefore there is no 
obvious lower boundary, in the current FG hypothesis, to the size of a nervous system that may 
exhibit a sleep-like behavior as an adaptive response to protease-generated fragments and modified 
protein complexes in which these fragments resided. C. elegans (~300 neurons) has a quiescent 
behavioral state during a period called lethargus
177-179
. It occurs before each of the four molts and 
exhibits some aspects of sleep, including higher arousal thresholds and a homeostatic response to 
mechanical stimulation during lethargus (specifically, an augmented quiescence after 
Page 24 of 58
John Wiley & Sons
Protein Science
25 
 
stimulation)
177
. The periods of lethargus involve alterations of the worm’s nervous system, 
suggesting that lethargus evolved to accommodate specific requirements of such alterations.  
Although it remains to be determined whether lethargus in C. elegans is fundamentally 
similar to sleep-like states in Drosophila, let alone to sleep in mammals, there are analogies 
between lethargus circuits and sleep regulation in larger animals, in that both settings involve 
proteins that control the epidermal growth factor (EGF) pathway, an ancient system whose 
functions encompass quiescence
177-181
. The FG hypothesis predicts higher levels of specific 
protease-generated protein fragments in some or most C. elegans neurons (and possibly in other cell 
types as well) shortly before lethargus. If the FG hypothesis proves relevant to the causation and 
function of sleep in mammals, the resulting understanding could be “turned around” by asking 
whether the lethargus in C. elegans involves the generation and degradation of specific fragments 
and the remodeling of protein complexes after fragments’ removal, and whether these processes are 
the molecular cause of lethargus. 
It is also unknown whether FG concepts might be relevant to organisms such as protists or 
other single-cell eukaryotes, which exhibit cycles of metabolic transitions under normal growth 
conditions
182
. Fundamentally, the FG hypothesis posits that a multitude of diverse protein fragments 
generated by nonprocessive proteases under conditions of daily life, as well as the necessity to 
remodel cleaved protein complexes can perturb the functioning of a cell. Being a challenge to stress 
response systems, these perturbations might require, at least in some cells, a quasi-periodic change 
of regimen that in more complex cellular assemblies would be called sleep. If the FG hypothesis 
proves germane to animals with elaborate nervous systems, this advance might also clarify whether 
FG concepts are also relevant to organisms where “sleep” is not an applicable term. 
 
The FG Hypothesis and Settings Other Than Sleep 
Although the FG hypothesis was described here in the context of sleep, the relevance of 
proposed mechanisms is not confined to neurons. Resetting of a circuit that involves a 
protease-generated protein fragment embedded in a multisubunit complex may involve the 
subunit-selective degradation of this fragment in any cell type and for reasons unrelated to sleep. 
Some of these reasons, such as the cycles of cleavage, subunit-selective degradation, and 
remodeling of cohesin complexes
125
, were described above (see a Fragment of Cohesin section). 
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Viewed generally, the concepts of the FG hypothesis should be relevant to any in vivo 
setting that involves accumulation of either a protease-generated fragment or a cleaved, 
un-remodeled protein complex, owing to insufficiently high rates of either degradation or 
remodeling, respectively. Increased levels of protein fragments and un-remodeled complexes in 
such cases may be accompanied by an (evolved) cellular adaptation that amounts to a period of 
quiescence for the cell type involved. “Quiescence” is defined here as the time during which the 
generation of fragments slows down, the activity of fragment-destroying pathways goes up, and the 
remodeling of cleaved complexes can take place after the fragments’ removal. Just two examples of 
the likely relevance of FG concepts outside sleep – muscle fatigue and mechanisms of memory – 
are briefly mentioned below, but many such settings may exist in all organisms, including 
prokaryotes, which contain both nonprocessive proteases and specific versions of the N-end rule 
pathway
125,156,183,184
.  
The roles of calpains in mammalian cells of different types are broadly similar to calpain 
functions in neurons. In myotubes of the skeletal muscle and in cardiomyocytes of the heart, 
calpains can cleave cytoskeletal proteins such as cortactin, vimentin, dystrophin, talin, troponin, 
actin, and titin [Fig. 3(#9, #10, #11, #12 #14)], and many other proteins as well. A detailed 
discussion of this subject is beyond the scope of the present paper, but it should be mentioned that 
the role of calpains in the cleavage of muscle proteins (with generation of protein fragments) and 
processive degradation of fragments under normal conditions or upon a strenuous exercise is a 
significant theme in muscle research
185-187
. The existing evidence is consistent with the relevance of 
FG concepts to muscle physiology. 
Another FG-related subject that will be mentioned but not discussed in detail are 
mechanisms of long-term memory. The previously proposed notion that calpain-mediated cleavages 
of specific cytoskeletal proteins such as spectrin may be relevant to memory processes
141
 remains 
unproven but likely, especially in view of many other calpain and caspase substrates in neurons that 
may be components of memory circuits (Figs. 3 and 4). There is growing evidence that cleavages of 
specific neuronal proteins by calpains and caspases play a role in long-term memory
117,188
. Studies 
of Ntan1
-/-
 mice, which lacked the Asn-specific Ntan1 Nt
N
-amidase and therefore lacked the 
Asn-deamidation branch of the Arg/N-end rule pathway [Fig. 2(A)], showed that these mice had 
significant defects in learning and long-term memory
189
. The recent discovery and molecular 
Page 26 of 58
John Wiley & Sons
Protein Science
27 
 
characterization of the Gln-specific Ntaq1 Nt
Q
-amidase, another component of the Arg/N-end rule 
pathway [Fig. 2(A)], has revealed that the previously identified fly mutant termed tungus, which 
had impaired long-term memory
190
, was apparently a null mutant in the Drosophila Ntaq1 
Nt
Q
-amidase
191
. In addition, physiological substrates of calpains and caspases can yield C-terminal 
fragments with N-terminal Asn or Gln. Such fragments are predicted substrates of Nt
N
-amidase and 
Nt
Q
-amidase, respectively [Fig. 3(#4, #5, #6, #12, #18, #34), Fig. 4(#9, #12, #18, #22, #23, #24), 
and data not shown]. This fact and the above genetic results
189-191
 strongly suggest a role of the 
Arg/N-end rule pathway in memory processes. 
 
Concluding Remarks 
The motivation to describe these linked ideas and their ramifications before experimental 
testing was four-fold. First, although the proposed model differs from previous thinking in research 
on sleep, the FG hypothesis is not inconsistent, to my knowledge, with any solid data about sleep. 
Second, in addition to possibly identifying the molecular cause and function of sleep, the FG 
hypothesis leads to new explanations of specific properties of sleep, including its evolutionary 
persistence and homeostatic character. Third, the concepts about protein fragments and their 
dynamics that underlie the FG hypothesis are likely to be relevant to other biological problems, 
including mechanisms of memory and the functioning of cells other than neurons. Fourth, the 
complexity of pathways encompassed by the FG hypothesis suggests that its verification won’t be a 
short affair. Experiments to address specific predictions of this hypothesis were recently initiated in 
our laboratory. 
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Figure Legends 
 
Figure 1. Generation, targeting and degradation of protein fragments, and remodeling of 
cleaved protein complexes. This diagram illustrates a multistage process that is expected to occur in 
a great variety of structural contexts and is as a part of reactions encompassed by the fragment 
generation (FG) hypothesis. The process begins with a proteolytic cleavage (lightning arrow) of an 
oligomeric (in this example, heterodimeric) protein by a nonprocessive protease such as, for 
example, calpain or caspase. The process continues with the subunit-selective degradation of a 
resulting C-terminal fragment either by the Arg/N-end rule pathway (in this example) or by another 
proteolytic pathway, and ends with reconstitution of the initial heterodimer. Such processes can 
involve both “soluble” and transmembrane proteins (Figs. 3-6). The arrangement of two subunits in 
the heterodimer is (arbitrarily) antiparallel, with N-termini and C-termini denoted by “N” and “C”, 
respectively. The rate constants k1-k6 illustrate the possibility of independent regulation of specific 
reaction steps. In this example, the N-terminal residue of the C-terminal fragment (it remains 
associated with the other subunit of heterodimer) is Gln (Q), a tertiary destabilizing residue 
[Fig. 2(A)]. The C-terminal fragment is sequentially modified by the Ntaq1 N
Q
-amidase and the 
Ate1 R-transferase (specific enzymes of the Arg/N-end rule pathway) [Fig. 2(A)], followed by 
polyubiquitylation of the fragment by N-recognins (ubiquitin ligases of the Arg/N-end rule 
pathway) such as the UBR1 E3 (only E3 component of the holoenzyme ligase is shown) and the 
proteasome-mediated degradation of the targeted C-terminal fragment. For illustrative purposes, 
each of two subunits is shown to consist of two domains. The N-terminal fragment of the cleaved 
subunit may also be targeted for degradation, either by the Ac/N-end rule pathway (via an 
Ac/N-degron of the fragment) in this example, [Fig. 2(B)], or by another proteolytic pathway. See 
Fig. 2 and the main text for additional details. 
 
Figure 2. The mammalian N-end rule pathway125,154,158,192. N-terminal residues are 
indicated by single-letter abbreviations for amino acids. A yellow oval denotes the rest of a protein 
substrate. E3 ubiquitin ligases of the N-end rule pathway are called N-recognins.  
A: The Arg/N-end rule pathway. “Primary”, “secondary” and “tertiary” denote 
mechanistically distinct subsets of destabilizing N-terminal residues. C* denotes oxidized 
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N-terminal Cys, either Cys-sulfinate or Cys-sulfonate, produced in vivo by reactions that require 
nitric oxide (NO) and oxygen. Oxidized N-terminal Cys is arginylated by ATE1-encoded isoforms 
of arginyl-tRNA-protein transferase (R-transferase), which also arginylates N-terminal Asp (D) and 
Glu (E). N-terminal Asn (N) and Gln (Q) are deamidated by the NTAN1-encoded Nt
N
-amidase and 
the NTAQ1-encoded Nt
Q
-amidase, respectively. In addition to the binding sites that recognize 
primary destabilizing N-terminal residues, the UBR1, UBR2, UBR4 and UBR5 (EDD) N-recognins 
contain binding sites for substrates (denoted by a larger oval) that lack N-degrons and have internal 
(non-N-terminal) degradation signals
125,192
. Polyubiquitylated Arg/N-end rule substrates are 
degraded to short peptides by the 26S proteasome. Hemin (Fe
3+
-heme) binds to R-transferase, 
inhibits its arginylation activity and accelerates its in vivo degradation
125,192,193
. Hemin also binds to 
UBR-type N-recognins
193
. Regulated degradation of specific proteins by the Arg/N-end rule 
pathway mediates the sensing of heme, NO, and oxygen; the elimination of misfolded proteins; the 
regulation of DNA repair; the fidelity of chromosome cohesion/segregation; the signaling by 
G proteins; the control of peptide import; the regulation of apoptosis, meiosis, viral infections, fat 
metabolism, cell migration, actin filaments, cardiovascular development, spermatogenesis, 
neurogenesis and memory; the functioning of adult organs, including the brain, muscle, testis and 
pancreas; and many functions in plants (Refs. 125,126,154-156,172,192,194,195 and Refs. therein). 
B: The Ac/N-end rule pathway. Although it is clear that this pathway is present in all or 
most eukaryotes
125
, it has been characterized, thus far , only in yeast
158
. This diagram illustrates the 
mammalian Ac/N-end rule pathway through an extrapolation from its S. cerevisiae version. Red 
arrow on the left indicates the removal of N-terminal Met by Met-aminopeptidases (MetAPs). This 
Met residue is retained if a residue at position 2 is nonpermissive (too large) for MetAPs. If the 
retained N-terminal Met or N-terminal Ala, Val, Ser, Thr, and Cys are followed by acetylation-
permissive residues, the above N-terminal residues are Nt-acetylated by ribosome-associated 
Nt-acetylases
196
. The resulting N-degrons are called Ac/N-degrons
158
. The term “secondary” refers 
to the necessity of modification (Nt-acetylation) of a destabilizing N-terminal residue before a 
protein can be recognized by a cognate N-recognin. Although the second-position Gly or Pro 
residues can be made N-terminal by MetAPs , few proteins with N-terminal Gly or Pro are 
Nt-acetylated
196
.  
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Figure 3. Calpain-generated C-terminal fragments of mammalian proteins that are either 
identified or predicted substrates of the Arg/N-end rule pathway. Each entry cites, on the left, a 
C-terminal (Ct) fragment and its N-terminal (Nt) residue (in red, using 3-letter abbreviations for 
amino acids), followed by a brief description of the full-length (uncleaved) precursor protein. The 
right side of each entry shows the cleavage site of a full-length protein, using single-letter 
abbreviations for amino acids. An enlarged residue name, in red (preceded by an arrowhead 
denoting the cleavage site), indicates the P1’ residue, i.e., the residue that becomes Nt upon the 
cleavage. Unless stated otherwise, the residue numbers are of human proteins. Two indicated 
residue numbers are the number of the first shown residue of a full-length protein and the number of 
its last residue, respectively.  
Most proteins on the list are present at least in neurons. These 34 proteins encompass the 
bulk of the previously characterized calpain substrates whose cleavage sites have been mapped and 
whose Ct fragments bear Nt residues that can be recognized by the Arg/N-end rule pathway 
[Fig. 2(A)]. Not shown are ~20 calpain-generated, previously mapped Ct fragments bearing Nt 
residues that are not recognized by the Arg/N-end rule pathway. The Nt residues of this class, 
including Ala, Ser and Thr, can be recognized by the Ac/N-end rule pathway [Fig. 2(B)] if these 
residues can be Nt-acetylated after having become Nt through a calpain-mediated cleavage. 
Whether these posttranslationally generated N-terminal residues can be efficaciously Nt-acetylated 
in vivo remains to be determined. In addition, there are ~40 other identified mammalian calpain 
substrates in which the exact locations of cleavage sites are unknown. Two calpain-generated Ct 
fragments, Asp-BCLXL (#16) and Arg-BID (#17), have been shown to be short-lived substrates of 
the Arg/N-end rule pathway
126
. Other Ct fragments on this list are predicted Arg/N-end rule 
substrates. The recent finding that 10 out of 10 Ct fragments (generated by caspases or calpains) 
that were predicted to be Arg/N-rule substrates were actually found to be such
126
 suggests that most 
Ct fragments on the present list are also degraded by the Arg/N-end rule pathway.  
Calpain-generated fragments: #1. Tyr-mGluR1α is the Ct fragment of the mGluR1α 
subunit of the transmembrane metabotropic glutamate receptor
197
. Receptors containing the calpain-
truncated mGluR1α subunit could elevate cytosolic Ca
2+
 but could not activate PI3K-Akt signaling 
pathways, in contrast to uncleaved receptors
197,198
. #2. Leu-NR2A is the Ct-fragment of the NR2A 
subunit of the transmembrane ionotropic glutamate receptor (NMDAR)
199
. The NR2B subunit of 
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NMDAR can also be cleaved by calpains
200
. Ct fragments of NR2A and NR2B contain domains 
required for the association of these subunits with synaptic proteins. NMDAR receptors lacking the 
Ct region of NR2A could function as glutamate-gated Ca
2+
 channels but the intracellular traffic of 
cleaved receptors and their electrophysiological properties were altered
201
. #3. Lys-ATP2B2 is the 
Ct fragment of the transmembrane ATP2B2 plasma membrane Ca
2+
 pump (PMCA) that ejects Ca
2+
 
from cells. This pump is activated either by the binding of Ca
2+
/calmodulin or by the calpain-
mediated truncation of ATP2B2 that generates the Lys-ATP2B2 fragment and thereby activates the 
pump
202
. #4. Gln-RYR1 is the Ct fragment of the RYR1 ryanodine receptor, a Ca
2+
 channel in the 
ER
203
 that mediates the efflux of Ca
2+
 from the ER into the cytosol. Calpain-mediated cleavage of 
RYR1 increases Ca
2+
 efflux
204
. #5. Gln-EGFR is one of the calpain-generated Ct fragments of the 
transmembrane epidermal growth factor (EGF) receptor protein kinase
205
. Remarkably, all 7 calpain 
cleavage sites in the cytosol-exposed domain of the 170-kDa EGFR contain P1’ residues (which 
become Nt upon a cleavage)
205
 that are destabilizing in the Arg/N-end rule [Fig. 2(A)]. 
#6. Asn-Cav1.1 is the Ct fragment of the voltage-gated transmembrane Ca
2+
 channel. This 
(apparently) calpain-generated fragment is noncovalently associated with the rest of the channel and 
can inhibit its activity. Upon dissociation from the channel, the Asn-Cav1.1 fragment migrates to the 
nucleus and functions as a transcriptional regulator
100,136,206,207
. #7. Arg-GlyT1A is the Ct fragment 
of the transmembrane GlyT1A glycine transporter
208
. Another Gly transporter, GlyT1B, is also 
cleaved by calpains, yielding the Arg-GlyT1B fragment
208
. These Ct fragments are still active as 
transporters but are impaired in their ability to remove Gly (an inhibitory neurotransmitter) from 
synaptic clefts
208
. #8. Leu-RAD21 is the Ct-fragment of the SCC1/RAD21 subunit of the 
chromosome-associated cohesin complex
209
. Calpain-mediated generation of Leu-RAD21 
contributes to the control  of chromosome cohesion/segregation, together with processes that 
include the separase-mediated cleavage of the same RAD21 subunit
144,151,209,210
 (see also Fig. 6F). 
#9. Lys-cortactin is the Ct fragment of cortactin, an actin-binding protein that regulates actin 
polymerization
211
. #10. Leu-vimentin is the Ct fragment of vimentin, a component of intermediate 
filaments
212
. #11. Arg-dystrophin is the Ct fragment of a major cytoskeletal protein in the skeletal 
muscle
213
. #12. Gln-talin is the Ct fragment of talin, an adaptor protein that interacts with the 
integrin family of cell adhesion transmembrane proteins
202,214,215
. #13. Leu-NF2 is the Ct fragment 
of NF2 (merlin), a tumor suppressor and cytoskeletal protein. Loss-of-function NF2 mutants result 
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in autosomal-dominant neurofibromatosis, a predisposition to specific kinds of brain tumors
216
 (see 
also Fig. 6E). #14. Leu-troponin T2 is the Ct fragment of the cardiac troponin T that is produced 
by calpain-1 from the troponin-containing cardiac myofibril complex
217
. #15. Glu-BAK is the Ct 
fragment of the proapoptotic regulator BAK. Glu-BAK is generated by calpain-1 in vitro and may 
be formed in vivo as well
218
. #16. Asp-BCLXL is the Ct fragment of the BCLXL antiapoptotic 
protein. In contrast to its full-length precursor, the Asp-BCLXL fragment is proapoptotic, and has 
been shown to be a short-lived substrate of the Arg/N-end rule pathway
126
. #17. Arg-BID is the Ct 
fragment of the proapoptotic BID regulator. The Arg-BID fragment is also proapoptotic, and in 
addition a short-lived Arg/N-end rule substrate
126
. #18. Asn-DSCR1 (RCAN1) is the Ct fragment of 
the Down syndrome critical region 1 protein DSCR1, which binds to Raf1, inhibits the phosphatase 
activity of calcineurin, and enhances its degradation. Calpain-generated Asn-DSCR1 does not bind 
to the Raf1 kinase
219
. #19. Arg-c-FOS is the Ct fragment of the c-FOS transcriptional regulator. c-
FOS is targeted for degradation through more than one degron, including the path that includes the 
cleavage by calpains
220
 and predicted degradation of Arg-c-FOS by the Arg/N-end rule pathway. 
#20. Arg-MEF2D is the Ct fragment of the MEF2D myocyte enhancer factor 2D, a transcriptional 
regulator that contributes to neuronal survival, development, and synaptic plasticity
221
. 
#21. Leu-STEP33 is the Ct fragment of the striatal-enriched STEP61 phosphatase, a brain-specific 
Tyr-phosphatase whose substrates include the MAPK-family kinases ERK1/2 and p38. 
Calpain-generated Leu-STEP33 fragment is lacks phosphatase activity
222
. #22. Leu-β-catenin is the 
Ct-fragment of β-catenin, a conditionally short-lived cytoskeletal protein and transcriptional 
regulator. The Leu-β-catenin fragment is a nuclear protein that activates specific genes in 
conjunction with other transcription factors
223
. #23. Arg-IGFBP2 is the Ct fragment of the insulin-
like growth factor binding protein-2 that is cleaved by calpain-2 at least in vitro
224
. #24. Glu-IκBα 
is the Ct fragment of the IκBα subunit of the autoinhibited NFκB-IκBα complex in which the NFκB 
transcriptional regulator is inhibited by IκBα. The IκBα subunit is targeted for degradation either 
through a conditional phosphodegron or through the calpain-mediated cleavage
225
 which produces 
Glu-IκBα, predicted to be an Arg/N-end rule substrate. #25. Phe-PKCγ is the Ct fragment of PKCγ, 
a Ser/Thr kinase of the PKC family
226
. The Phe-PKCγ fragment is constitutively active as a kinase, 
because it lacks the regulatory Nt domain of the full-length PKCγ kinase
226
. #26. Leu-CAMK-IV is 
the Ct fragment of the Ca
2+
/calmodulin-dependent kinase-IV. This fragment lacks kinase activity
227
. 
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#27. Lys-PKCα is the Ct fragment of PKCα, a broadly expressed Ser/Thr kinase of the PKC 
family
226
. Being catalytically active but no longer controlled by the regulatory Nt domain of the 
full-length PKCα, the Lys-PKCα fragment can be toxic, for example, upon its formation in an 
ischemic heart
228
. #28. Arg-p39 is the Ct fragment of the p39 activator of the Cdk5 protein 
kinase
229
. The indicated cleavage site is located immediately downstream of 2 other closely spaced 
(and strongly conserved) calpain cleavage sites in p39. A cleavage at any one of these sites yields a 
predicted Arg/N-end rule substrate (see Fig. 6H). #29. Lys-GAD65-2 is the Ct fragment of the 
glutamic acid decarboxylase-65-2 (GAD65-2), which is bound to membranes of synaptic vesicles 
and mediates the synthesis of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) from the 
excitatory neurotransmitter glutamate. Calpain-generated Lys-GAD65-2 retains the enzymatic 
activity of uncleaved GAD65-2 but is no longer associated with synaptic vesicles
230-232
 (see also 
Fig. 6G). #30. Arg-caspase-9 is the Ct fragment of caspase-9, which can be inactivated by 
calpains
233
, followed by the (predicted) degradation of the Arg-caspase-9 fragment by the 
Arg/N-end rule pathway. #31. Leu-calpain-1 is the Ct fragment of human calpain-1. The 
Leu-calpain-1 fragment is an activated form of this calpain
234,235
. #32. Asp-calpain (reg. subunit) is 
the Ct fragment of the calpain regulatory subunit that is cleaved by activated calpains
119,123
. 
#33. Lys-calpain-2 is the Ct fragment of human calpain-2, an activated form of this calpain
119-123
. 
#34. Asn-calpain-B is the calpain-generated Ct fragment of one of two major D. melanogaster 
calpains and an activated form of this calpain
236
. 
 
Figure 4. Caspase-generated C-terminal fragments of mammalian proteins that are either 
identified or predicted substrates of the Arg/N-end rule pathway. The 30 caspase substrates cited in 
this list are a small fraction of ~1,000 known and mapped mammalian caspase substrates (see the 
main text). For designations, including residue numbering, see the legend to Fig. 3.  
The first 8 caspase-generated, proapoptotic Ct fragments are the recently examined and 
confirmed short-lived substrates of the Arg/N-end rule pathway
126
. #1. Cys-RIPK1 is the 
proapoptotic Ct fragment of the RIPK1 kinase, a regulator of apoptosis, necroptosis and other 
processes, including antiviral responses that do not involve cell death
128,237-239
 (see also Fig. 6A). 
#2. Cys-TRAF1 is the proapoptotic Ct fragment of TRAF1, which functions to minimize the 
activation of caspase-8 and other proapoptotic reactions, in part by contributing to up-regulation of 
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the antiapoptotic NF-κB regulon
128,240
. #3. Asp-BRCA1 is the proapoptotic Ct fragment of BRCA1, 
a RING-type E3 ubiquitin ligase that functions as a tumor suppressor and participates in DNA 
repair, cell-cycle regulation, transcriptional control, and other processes
241,242
 (see also Fig. 6B). 
#4. Leu-LIMK1 is the proapoptotic Ct fragment of LIMK1, a Ser/Thr kinase that functions, in 
particular, as a downstream effector of Rho signaling pathways and regulator of actin dynamic
243
. 
#5. Tyr-NEDD9 is the proapoptotic Ct fragment of NEDD9, a scaffolding protein whose functions 
include cell attachment, migration, and mitotic control
244
. #6. Arg-BIMEL is the proapoptotic Ct 
fragment of BIMEL a regulator of apoptosis
128
. #7. Asp-EPHA4 is the proapoptotic Ct fragment of 
EPHA4, a member of the family of more than 10 mammalian “dependence”  receptors (DpRs). 
These structurally distinct receptors are functionally analogous because of their ability to mediate 
two opposite physiological outcomes. In the presence of its cognate ligand, a DpR receptor activates 
signaling pathways that mediate cell survival, migration, proliferation or differentiation. In the 
absence of its ligand, a dependence receptor produces a proapoptotic signal, often through the 
formation, by caspases or other nonprocessive proteases, of a C-terminal proapoptotic fragment that 
functions in the cytosol and/or the nucleus
245,246
. #8. Tyr-MET is the proapoptotic Ct fragment of 
MET, another dependence receptor, with functions in embryonic development and organ 
formation
245,246
. 
The next 6 caspase-generated proapoptotic Ct fragments are predicted substrates of the 
Arg/N-end rule pathway
126
. #9. Asn-PKCδ is the proapoptotic Ct fragment of the PKCδ protein 
kinase
247
. #10. Lys-PKCθ is the proapoptotic Ct fragment of the PKCθ protein kinase
248
. 
#11. Trp-ETK is the proapoptotic Ct fragment of the ETK/BMC tyrosine kinase, a member of the 
Btk/Tek kinase family
249
. #12. Gln-SLK is the proapoptotic Ct fragment of SLK, a STE20-related 
protein kinase that plays a role in regulation of actin fibers
250
. #13. Ile-HPK1 is the proapoptotic Ct 
fragment of HPK1, the a STE20-related protein kinase whose functions include stimulation of the 
stress-activated protein kinases SAPKs/JNKs and the NF-κB transcriptional regulon
251
. 
#14. Ile-MLH1 is the proapoptotic Ct fragment of the MLH1 DNA mismatch repair protein
252
. 
The next 16 caspase-generated Ct fragments and predicted substrates of the Arg/N-end rule 
pathway that are not necessarily proapoptotic. These likely Arg/N-end rule substrates are cited to 
illustrate the remarkable diversity of their precursor proteins. #15. Tyr-CYLD is the Ct fragment of 
a deubiquitylase that regulates apoptosis and necroptosis
253
 (see also Fig. 6D). #16. Leu-p21
Cip1/Waf1
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is the Ct fragment of p21
Cip1/Waf
, an inhibitor of cell division
254
. #17. Arg-IP3R is the Ct fragment 
of the inositol 1,4,5-triphosphate receptor
255
. #18. Asn-LMN1 is the Ct fragment of lamin-A, a 
component of nuclear lamina
256
. #19. Arg-ETS-1 is the Ct fragment of a transcription factor
257
. 
#20. Tyr-TOP1 is the Ct fragment of type I DNA topoisomerase
258
. #21. Leu-MEFD2 is the Ct 
fragment of a transcription factor
259
. #22. Asn-DNA-PK is the Ct fragment of the DNA-dependent 
protein kinase
260
. #23. Asn-CAD1 is the Ct fragment of E-cadherin, an adhesion receptor
261
. 
#24. Gln-Synphilin-1 is the Ct fragment of synphilin-1, a ligand of α-synuclein
262
 (see also 
Fig. 6C). #25. Tyr-ACINUS is the Ct fragment of a mediator of apoptotic chromatin 
condensation
263
. #26. Lys-PLECTIN is the Ct fragment of a cytoskeletal protein
264
. 
#27. Cys-CCNE1 is the Ct fragment of a specific G1/S cyclin
265
 . #28. His-PMCA4b is the Ct 
fragment of a Ca
2+
 extrusion pump
266
. #29. Asp-CDC42 is the Ct fragment of CDC42, a RAS 
superfamily member
267
. #30. Tyr-iPLA2 is the Ct fragment of the phospholipase A2 (Ref. 268). 
 
Figure 5. Examples of predicted substrates of the Arg/N-end rule pathway that are 
produced by nonprocessive proteases other than Met-aminopeptidases, calpains or caspases. For 
designations, see the legend to Fig. 3. Although some of the proteases mentioned below (e.g., furin) 
are usually localized outside the nucleus and cytosol, the cited papers indicate that these proteases 
can also generate cytosolic or nuclear Ct protein fragments. #1. Furin-mediated cleavage of the 
bacterial (Bortedella) DNT toxin produces the Glu-DNT fragment, which translocates into the 
cytosol
269
. #2. Cleavage by γ-secretase generates the Arg-CAD1 fragment of E-cadherin
261
. 
#3. Another predicted Arg/N-end rule substrate that can be produced by γ-secretase is Gln-ROBO1, 
the Ct fragment of the transmembrane ROBO1 receptor
270
. #4. Proteinase-3 (myeloblastin), a 
cytosolic/nuclear protease, produces Arg-p21, the Ct fragment of p21, a cell division inhibitor 
271
. 
#5. The Omi/Htr2 protease can cleave the cIAP1 protein (an antiapoptotic regulator and inhibitor of 
caspases), yielding the Asn-cIAP1 Ct fragment
272
. #6. An intracellular form of elastase cleaves the 
PML-RARα oncoprotein fusion, yielding the Tyr-PML-RARα Ct fragment
273
. #7. The 
aminopeptidase PILSAP removes the first 9 residues of the kinase PDK1, yielding the 
enzymatically active Asp-PDK1 Ct fragment
274
. 
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Figure 6. Evolutionary conservation of caspase (A-D) and calpain (E-H) cleavage sites, and the 
conservation of destabilizing activity of P1’ residues in these sites. The caspase cleavage sites in A-
D (positions P4-P1) are framed by gray rectangles. The indicated residue numbers, including those 
of P1’ residues (in color), are of human versions of the full-length proteins. In many caspase and 
calpain cleavage sites (including those shown in Figs. 3 and 4), P1’ residues are completely 
conserved at least among vertebrates. By contrast, in some cleavage sites, for example those of 
BRCA1 in B (Fig. 4 (#3)), synphilin-1 in C (Fig. 4(#24)), CYLD in D (Fig. 4(#15)), and p39 in H 
(Fig. 3(#28)), the P1’ residues (they are shown in different colors, with predominant identities in 
red) are not conserved among vertebrates. Remarkably, however, their destabilizing activity in the 
Arg/N-end rule pathway [Fig. 2(A)] is invariably conserved (see the main text). For brief 
descriptions of the other cited caspase- or calpain-cleaved proteins RIPK1, NF2, RAD21 and 
GAD65, see Fig. 4(#1), Fig. 3(#13), Fig. 3(#8), and Fig. 3(#29), respectively. See also the Protein 
Fragments, Their Generation In Spite of Deleterious Effects, and the Evolutionary Persistence of 
Sleep section. 
 
Figure 7. Monitoring protein fragments and reacting to their accumulation. This diagram 
mentions PANX1, a transmembrane protein and conditional ATP release channel (light blue oval 
near the top on the left) as a possible example of a sensor-effector protein. A cleavage of PANX1 is 
depicted to induce its activity as an ATP release channel (red semi-oval near the top on the right). 
By linking fragment formation to upregulation of somnogenic pathways that involve extracellular 
ATP and cytokines (see the FG Hypothesis and Somnogenic Activity of Cytokines section), this 
arrangement would make it possible for sleep-regulating pathways to gauge an increased production 
of many different fragments (green ovals and rectangles) during wakefulness, and to react by 
increasing the levels of somnogenic compounds, for example, extracellular adenosine, ATP or 
PGD2. The PANX1 channel was used to illustrate this regulatory arrangement because PANX1 has 
been shown to be strongly activated upon its cleavage by caspases
131,132
. See also the Monitoring 
Protein Fragments and Reacting to Their Accumulation section.  
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